{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:14Z","timestamp":1781639714095,"version":"3.54.5"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01446-z","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:55:06Z","timestamp":1772632506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies"],"prefix":"10.1186","volume":"32","author":[{"given":"Yashaswini","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmini","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil Viren","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa Gangadhar","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babitha Kampa","family":"Sundara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"1446_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acsomega.3c03337","volume":"8","author":"A Akhlaq","year":"2023","unstructured":"Akhlaq A, Ashraf M, Omer MO, Altaf I. Carvacrol-fabricated chitosan nanoparticle synergistic potential with topoisomerase inhibitors on breast and cervical cancer cells. ACS Omega. 2023;8:1\u201313.","journal-title":"ACS Omega"},{"key":"1446_CR2","first-page":"1","volume":"67","author":"J Akinyelu","year":"2022","unstructured":"Akinyelu J, Oladimeji O, Daniels A, Singh M. Folate-targeted doxorubicin delivery to breast and cervical cancer cells using a chitosan-gold nano-delivery system. J Drug Deliv Sci Technol. 2022;67:1\u201310.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1446_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ygyno.2025.09.001","volume":"202","author":"J An","year":"2025","unstructured":"An J, Li G, Zhang Y, Feng M, Kong W, Jiang H, et al. Sacituzumab govitecan in Chinese patients with recurrent\/metastatic cervical cancer: results from the phase 2 EVER-132-003 basket study (NCT05119907). Gynecol Oncol. 2025;202:33\u201340.","journal-title":"Gynecol Oncol"},{"key":"1446_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-84203-8","volume":"15","author":"S Anjum","year":"2025","unstructured":"Anjum S, Akhtar A, Aldaqal SM, Abduh MS, Ahmad H, Mustafa R, et al. Enhanced targeted treatment of cervical cancer using nanoparticle-based doxycycline delivery system. Sci Rep. 2025;15:1\u201320.","journal-title":"Sci Rep"},{"key":"1446_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:1\u201313.","journal-title":"Lancet Glob Health"},{"key":"1446_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1517\/13543784.4.12.1217","volume":"4","author":"O Balat","year":"1995","unstructured":"Balat O, Verschraegen C. Section review: oncologic, endocrine & metabolic: topoisomerase I inhibitors in gynaecologic cancers. Expert Opin Investig Drugs. 1995;4:1217\u201312322.","journal-title":"Expert Opin Investig Drugs"},{"key":"1446_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2024.107431","volume":"209","author":"AD Bondarev","year":"2024","unstructured":"Bondarev AD, Jonsson J, Chubarev VN, Tarasov VV, Lagunas-Rangel FA, Schi\u00f6th HB. Recent developments of topoisomerase inhibitors: clinical trials, emerging indications, novel molecules and global sales. Pharmacol Res. 2024;209:1\u201320.","journal-title":"Pharmacol Res"},{"key":"1446_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tvr.2022.200238","volume":"13","author":"CA Burmeister","year":"2022","unstructured":"Burmeister CA, Khan SF, Sch\u00e4fer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res. 2022;13:1\u201314.","journal-title":"Tumour Virus Res"},{"key":"1446_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tvr.2024.200309","volume":"19","author":"CA Burmeister","year":"2025","unstructured":"Burmeister CA, Khan SF, Prince S. Drugs and drug targets for the treatment of HPV-positive cervical cancer. Tumour Virus Res. 2025;19:1\u201314.","journal-title":"Tumour Virus Res"},{"key":"1446_CR10","first-page":"229","volume":"112","author":"A Buskwofie","year":"2020","unstructured":"Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. J Natl Med Assoc. 2020;112:229\u201332.","journal-title":"J Natl Med Assoc"},{"key":"1446_CR11","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/14756366.2020.1821676","volume":"35","author":"K Buzun","year":"2020","unstructured":"Buzun K, Bielawska A, Bielawski K, Gornowicz A. DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme Inhib Med Chem. 2020;35:1781\u201399.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"1446_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/02841869109092379","volume":"30","author":"F Calero","year":"1991","unstructured":"Calero F, Rodriguez-Escudero F, Jimeno J, Mendana J, Iglesias J, Murillo F, et al. Single agent epirubicin in squamous cell cervical cancer: a phase II trial. Acta Oncol. 1991;30:325\u20137.","journal-title":"Acta Oncol"},{"key":"1446_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1028-4559(08)60048-0","volume":"47","author":"JR Chen","year":"2008","unstructured":"Chen JR, Yang YC, Chen TC, Lai JC, Chang SJ, Chang CL, et al. Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated liposomal doxorubicin (lipo-dox). Taiwan J Obstet Gynecol. 2008;47:1\u20135.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"1446_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biopha.2015.08.034","volume":"75","author":"Y Cheng","year":"2015","unstructured":"Cheng Y, Chen G, Hu M, Huang J, Li B, Zhou L, et al. Has-miR-30a regulates autophagic activity in cervical cancer upon hydroxycamptothecin exposure. Biomed Pharmacother. 2015;75:67\u201374.","journal-title":"Biomed Pharmacother"},{"key":"1446_CR15","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.bmc.2009.12.069","volume":"18","author":"HJ Cho","year":"2010","unstructured":"Cho HJ, Jung MJ, Woo S, Kim J, Lee ES, Kwon Y, et al. New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers. Bioorg Med Chem. 2010;18:1010\u20137.","journal-title":"Bioorg Med Chem"},{"key":"1446_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00280-001-0407-1","volume":"49","author":"G D'Agostino","year":"2002","unstructured":"D\u2019Agostino G, Distefano M, Greggi S, Salerno M, Ferrandina G, Poerio A, et al. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin. Cancer Chemother Pharmacol. 2002;49:256\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1446_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1006\/gyno.2002.6609","volume":"85","author":"CJ Dunton","year":"2002","unstructured":"Dunton CJ, King SA, Neufeld J, Tolosa J, Perez G, et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol Oncol. 2002;85:185\u20137.","journal-title":"Gynecol Oncol"},{"key":"1446_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1080\/14656566.2019.1621292","volume":"20","author":"MP Economides","year":"2019","unstructured":"Economides MP, McCue D, Borthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother. 2019;20:1637\u201344.","journal-title":"Expert Opin Pharmacother"},{"key":"1446_CR19","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.bpj.2024.05.004","volume":"123","author":"S Evoli","year":"2024","unstructured":"Evoli S, Kariyawasam NL, Nitiss KC, Nitiss JL, Wereszczynski J. Modeling allosteric mechanisms of eukaryotic type II topoisomerases. Biophys J. 2024;123:1620\u201334.","journal-title":"Biophys J"},{"key":"1446_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2009.12.027","volume":"117","author":"M Fabbro","year":"2010","unstructured":"Fabbro M, Gladieff L, Guichard F, El Demery M, Dalenc F, Kerr C, et al. Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. Gynecol Oncol. 2010;117:1\u20135.","journal-title":"Gynecol Oncol"},{"key":"1446_CR21","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.21873\/anticanres.14505","volume":"40","author":"M Fathy","year":"2020","unstructured":"Fathy M, Sun S, Zhao QL, Abdel-Aziz M, Abuo-Rahma GE, Awale S, et al. A new ciprofloxacin-derivative inhibits proliferation and suppresses the migration ability of HeLa cells. Anticancer Res. 2020;40:5025\u201333.","journal-title":"Anticancer Res"},{"key":"1446_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ygyno.2012.12.003","volume":"128","author":"G Ferrandina","year":"2013","unstructured":"Ferrandina G, Distefano MG, De Vincenzo R, Salutari V, Petrillo M, Scarciglia ML, et al. Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results. Gynecol Oncol. 2013;128:518\u201323.","journal-title":"Gynecol Oncol"},{"key":"1446_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","volume":"136","author":"RG Fu","year":"2017","unstructured":"Fu RG, Sun Y, Sheng WB, Liao DF. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur J Med Chem. 2017;136:195\u2013211.","journal-title":"Eur J Med Chem"},{"key":"1446_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20022727.2017.1335567","volume":"8","author":"S Gupta","year":"2017","unstructured":"Gupta S, Gupta MK. Possible role of nanocarriers in drug delivery against cervical cancer. Nano Rev Exp. 2017;8:1\u201326.","journal-title":"Nano Rev Exp"},{"key":"1446_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2019.102962","volume":"88","author":"MR Haider","year":"2019","unstructured":"Haider MR, Ahmad K, Siddiqui N, Ali Z, Akhtar MJ, Fuloria N, et al. Novel 9-(2-(1-arylethylidene) hydrazinyl) acridine derivatives: target Topoisomerase 1 and growth inhibition of HeLa cancer cells. Bioorg Chem. 2019;88:1\u201315.","journal-title":"Bioorg Chem"},{"key":"1446_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/00002018-200629030-00005","volume":"29","author":"JT Hartmann","year":"2006","unstructured":"Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II\u2014mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 2006;29:209\u201330.","journal-title":"Drug Saf"},{"key":"1446_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1871520622666220513160706","volume":"23","author":"YM Hegde","year":"2023","unstructured":"Hegde YM, Theivendren P, Srinivas G, Palanivel M, Shanmugam N, Kunjiappan S, et al. A recent advancement in nanotechnology approaches for the treatment of cervical cancer. Anticancer Agents Med Chem. 2023;23:37\u201359.","journal-title":"Anticancer Agents Med Chem."},{"key":"1446_CR28","first-page":"5077","volume":"49","author":"YH Hsiang","year":"1989","unstructured":"Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077\u201382.","journal-title":"Cancer Res"},{"key":"1446_CR29","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05838521. Accessed on 18 January 2026."},{"key":"1446_CR30","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer. Accessed on 18 January 2026."},{"key":"1446_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/jjco\/hyr017","volume":"41","author":"JH Hwang","year":"2011","unstructured":"Hwang JH, Lim MC, Seo SS, Park SY, Kang S. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. Jpn J Clin Oncol. 2011;41:624\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"1446_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejps.2016.09.039","volume":"96","author":"D Iacopetta","year":"2017","unstructured":"Iacopetta D, Rosano C, Puoci F, Parisi OI, Saturnino C, Caruso A, et al. Multifaceted properties of 1, 4-dimethylcarbazoles: focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors. Eur J Pharm Sci. 2017;96:263\u201372.","journal-title":"Eur J Pharm Sci"},{"key":"1446_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00005-21","volume":"12","author":"P Kaminski","year":"2021","unstructured":"Kaminski P, Hong S, Kono T, Hoover P, Laimins L. Topoisomerase 2\u03b2 induces DNA breaks to regulate human papillomavirus replication. Mbio. 2021;12:1\u201311.","journal-title":"Mbio"},{"key":"1446_CR34","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.ejmech.2017.10.054","volume":"143","author":"J Kovvuri","year":"2018","unstructured":"Kovvuri J, Nagaraju B, Nayak VL, Akunuri R, Rao MN, Ajitha A, et al. Design, synthesis and biological evaluation of new \u03b2-carboline-bisindole compounds as DNA binding, photocleavage agents and topoisomerase I inhibitors. Eur J Med Chem. 2018;143:1563\u201377.","journal-title":"Eur J Med Chem"},{"key":"1446_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2021.105349","volume":"116","author":"S Kunwar","year":"2021","unstructured":"Kunwar S, Hwang SY, Katila P, Seo M, Kadayat TM, Kwon Y, et al. 4-Flourophenyl-substituted 5H-indeno [1, 2-b] pyridinols with enhanced topoisomerase II\u03b1 inhibitory activity: synthesis, biological evaluation, and structure\u2013activity relationships. Bioorg Chem. 2021;116:1\u201311.","journal-title":"Bioorg Chem"},{"key":"1446_CR36","first-page":"1","volume":"32","author":"JE Kurtz","year":"2012","unstructured":"Kurtz JE, Freyer G, Joly F, Gladieff L, Kaminski MC, Fabbro M, et al. Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial. Anticancer Res. 2012;32:1\u20135.","journal-title":"Anticancer Res"},{"key":"1446_CR37","first-page":"325","volume":"2","author":"L Larasati","year":"2011","unstructured":"Larasati L, Kusharyanti I, Hermawan A, Susidarti RA, Meiyanto E. Naringenin enhances the anti-tumor effect of doxorubicin on HeLa cervical cancer cells through cytotoxic activity and apoptosis induction. Indones J Cancer Chemoprev. 2011;2:325\u201333.","journal-title":"Indones J Cancer Chemoprev"},{"key":"1446_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ijgc-00009577-200509000-00014","volume":"15","author":"LH L\u00ea","year":"2005","unstructured":"L\u00ea LH, Swenerton KD, Elit L, Provencher DM, Stuart GC, Le T, et al. Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer. 2005;15:799\u2013806.","journal-title":"Int J Gynecol Cancer"},{"key":"1446_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emm.2013.149","volume":"46","author":"SJ Lee","year":"2014","unstructured":"Lee SJ, Hwang SO, Noh EJ, Kim DU, Nam M, Kim JH, et al. Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. Exp Mol Med. 2014;46:1\u20138.","journal-title":"Exp Mol Med"},{"key":"1446_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-019-0089-y","volume":"25","author":"S Lee","year":"2019","unstructured":"Lee S, Ho JY, Liu JJ, Lee H, Park JY, Baik M, et al. CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer. Mol Med. 2019;25:1\u20138.","journal-title":"Mol Med"},{"key":"1446_CR41","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1023\/A:1008221310453","volume":"8","author":"A Lissoni","year":"1997","unstructured":"Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8:969\u201372.","journal-title":"Ann Oncol"},{"key":"1446_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2008.08.037","volume":"274","author":"Y Liu","year":"2009","unstructured":"Liu Y, Xing H, Weng D, Song X, Qin X, Xia X, et al. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett. 2009;274:47\u201353.","journal-title":"Cancer Lett"},{"key":"1446_CR43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000072333","volume":"65","author":"S Machida","year":"2003","unstructured":"Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, et al. Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology. 2003;65:102\u20137.","journal-title":"Oncology"},{"key":"1446_CR44","first-page":"1","volume":"111","author":"TB Magar","year":"2021","unstructured":"Magar TB, Seo SH, Shrestha A, Kim JA, Kunwar S, Bist G, et al. Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase II\u03b1 inhibitors. Bioorg Chem. 2021;111:1\u201315.","journal-title":"Bioorg Chem"},{"key":"1446_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ejmech.2015.08.032","volume":"102","author":"P Majumdar","year":"2015","unstructured":"Majumdar P, Bathula C, Basu SM, Das SK, Agarwal R, Hati S, et al. Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity. Eur J Med Chem. 2015;102:540\u201351.","journal-title":"Eur J Med Chem"},{"key":"1446_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2011.04.013","volume":"122","author":"N Manci","year":"2011","unstructured":"Manci N, Marchetti C, Di Tucci C, Giorgini M, Esposito F, Palaia I, et al. A prospective phase II study of topotecan (Hycamtin\u00ae) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2011;122:1\u20136.","journal-title":"Gynecol Oncol"},{"key":"1446_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bies.202000286","volume":"43","author":"SJ McKie","year":"2021","unstructured":"McKie SJ, Neuman KC, Maxwell A. DNA topoisomerases: advances in understanding of cellular roles and multi-protein complexes via structure-function analysis. BioEssays. 2021;43:1\u201319.","journal-title":"BioEssays"},{"key":"1446_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ijc.2910590506","volume":"59","author":"HL McLeod","year":"1994","unstructured":"McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, Van Der Zee AG, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer. 1994;59:607\u201311.","journal-title":"Int J Cancer"},{"key":"1446_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","volume":"10","author":"CA Moody","year":"2010","unstructured":"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550\u201360.","journal-title":"Nat Rev Cancer"},{"key":"1446_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1006\/gyno.2000.6024","volume":"81","author":"LI Muderspach","year":"2001","unstructured":"Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81:213\u20135.","journal-title":"Gynecol Oncol"},{"key":"1446_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bmc.2019.01.011","volume":"27","author":"B Nagaraju","year":"2019","unstructured":"Nagaraju B, Kovvuri J, Kumar CG, Routhu SR, Shareef MA, Kadagathur M, et al. Synthesis and biological evaluation of pyrazole linked benzothiazole-\u03b2-naphthol derivatives as topoisomerase I inhibitors with DNA binding ability. Bioorg Med Chem. 2019;27:708\u201320.","journal-title":"Bioorg Med Chem"},{"key":"1446_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1039\/C9TB00336C","volume":"7","author":"A Nandi","year":"2019","unstructured":"Nandi A, Ghosh C, Bajpai A, Basu S. Graphene oxide nanocells for impairing topoisomerase and DNA in cancer cells. J Mater Chem B. 2019;7:1\u20139.","journal-title":"J Mater Chem B"},{"key":"1446_CR53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9:338\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1446_CR54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.26650\/IstanbulJPharm.2022.1105443","volume":"52","author":"H Nur \u00c7elebio\u011flu","year":"2022","unstructured":"Nur \u00c7elebio\u011flu H, Becit M, Caglayan A, Ayd\u0131n Dilsiz S. Effects of thymoquinone and etoposide combination on cell viability and genotoxicity in human cervical cancer hela cells. Istanbul J Pharm. 2022;52:258\u201364.","journal-title":"Istanbul J Pharm"},{"key":"1446_CR55","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2391::AID-CNCR14>3.0.CO;2-M","volume":"79","author":"CA Papadimitriou","year":"1997","unstructured":"Papadimitriou CA, Dimopoulos MA, Giannakoulis N, Sarris K, Vassilakopoulos G, Akrivos T, et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer. 1997;79:2391\u20135.","journal-title":"Cancer"},{"key":"1446_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0090-8258(90)90338-L","volume":"37","author":"P Pfeiffer","year":"1990","unstructured":"Pfeiffer P, Cold S, Bertelsen K, Panduro J, Sandberg E, Rose C. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy. Gynecol Oncol. 1990;37:230\u20133.","journal-title":"Gynecol Oncol"},{"key":"1446_CR57","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1021\/cr900097c","volume":"109","author":"Y Pommier","year":"2009","unstructured":"Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009;109:2894\u2013902.","journal-title":"Chem Rev"},{"key":"1446_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1021\/cb300648v","volume":"8","author":"Y Pommier","year":"2013","unstructured":"Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013;8:82\u201395.","journal-title":"ACS Chem Biol"},{"key":"1446_CR59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","volume":"23","author":"Y Pommier","year":"2022","unstructured":"Pommier Y, Nussenzweig A, Takeda S, Austin C. Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022;23:407\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1446_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15082222","volume":"15","author":"I Psilopatis","year":"2023","unstructured":"Psilopatis I, Garmpis N, Garmpi A, Vrettou K, Sarantis P, Koustas E, et al. The emerging role of histone deacetylase inhibitors in cervical cancer therapy. Cancers. 2023;15:1\u201320.","journal-title":"Cancers"},{"key":"1446_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13205-025-04556-3","volume":"15","author":"N Purohit","year":"2025","unstructured":"Purohit N, Mishra Y, Hazarika P, Gopalakrishnan AV, Murali R. Pathways to precision medicine in cervical cancer: a comprehensive review of small molecule inhibitors, biomarkers and computational approaches. 3 Biotech. 2025;15:1\u201329.","journal-title":"3 Biotech"},{"key":"1446_CR62","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ejmech.2017.12.050","volume":"144","author":"VG Reddy","year":"2018","unstructured":"Reddy VG, Bonam SR, Reddy TS, Akunuri R, Naidu VG, Nayak VL, et al. 4\u03b2-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-II\u03b1 inhibition and potential anticancer agents for prostate cancer. Eur J Med Chem. 2018;144:595\u2013611.","journal-title":"Eur J Med Chem"},{"key":"1446_CR63","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ygyno.2005.11.048","volume":"102","author":"PG Rose","year":"2006","unstructured":"Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;102:210\u20133.","journal-title":"Gynecol Oncol"},{"key":"1446_CR64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/14756366.2018.1507029","volume":"34","author":"K Sangpheak","year":"2019","unstructured":"Sangpheak K, Mueller M, Darai N, Wolschann P, Suwattanasophon C, Ruga R, et al. Computational screening of chalcones acting against topoisomerase II\u03b1 and their cytotoxicity towards cancer cell lines. J Enzyme Inhib Med Chem. 2019;34:134\u201343.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"1446_CR65","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ejmech.2017.12.055","volume":"144","author":"M Sathish","year":"2018","unstructured":"Sathish M, Kavitha B, Nayak VL, Tangella Y, Ajitha A, Nekkanti S, et al. Synthesis of podophyllotoxin linked \u03b2-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors. Eur J Med Chem. 2018;144:557\u201371.","journal-title":"Eur J Med Chem"},{"key":"1446_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-025-23118-z","volume":"25","author":"G Sathiyaseelan","year":"2025","unstructured":"Sathiyaseelan G, Hashim SM, Nawi AM. Sociocultural factors influencing women\u2019s adherence to colorectal, breast, and cervical cancer screening: a systematic review. BMC Public Health. 2025;25:1\u201342.","journal-title":"BMC Public Health"},{"key":"1446_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000535491","volume":"47","author":"P Sch\u00f6ffski","year":"2024","unstructured":"Sch\u00f6ffski P, Wang CC, Sch\u00f6ffski MP, Wozniak A. Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates. Oncol Res Treat. 2024;47:18\u201341.","journal-title":"Oncol Res Treat"},{"key":"1446_CR68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.15430\/JCP.2015.20.2.85","volume":"20","author":"YH Seo","year":"2015","unstructured":"Seo YH. Dual inhibitors against topoisomerases and histone deacetylases. J Cancer Prev. 2015;20:85\u201391.","journal-title":"J Cancer Prev"},{"key":"1446_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41231-019-0050-7","volume":"4","author":"AA Seyhan","year":"2019","unstructured":"Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide\u2013identification of problems and overcoming obstacles. Transl Med Commun. 2019;4:1\u20139.","journal-title":"Transl Med Commun"},{"key":"1446_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16040680","volume":"16","author":"NK Sharma","year":"2024","unstructured":"Sharma NK, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar PV, et al. Understanding cancer\u2019s defense against topoisomerase-active drugs: a comprehensive review. Cancers. 2024;16:1\u201332.","journal-title":"Cancers"},{"key":"1446_CR71","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1016\/j.bmc.2018.09.021","volume":"26","author":"A Shrestha","year":"2018","unstructured":"Shrestha A, Park S, Jang HJ, Katila P, Shrestha R, Kwon Y, et al. A new phenolic series of indenopyridinone as topoisomerase inhibitors: design, synthesis, and structure-activity relationships. Bioorg Med Chem. 2018;26:5212\u201323.","journal-title":"Bioorg Med Chem"},{"key":"1446_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2020.103631","volume":"96","author":"I Singh","year":"2020","unstructured":"Singh I, Luxami V, Paul K. Synthesis of naphthalimide-phenanthro [9, 10-d] imidazole derivatives: in vitro evaluation, binding interaction with DNA and topoisomerase inhibition. Bioorg Chem. 2020;96:1\u201311.","journal-title":"Bioorg Chem"},{"key":"1446_CR73","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s00044-022-02862-6","volume":"31","author":"Y Song","year":"2022","unstructured":"Song Y, Zhu X, Yang K, Feng S, Zhang Y, Dong J, et al. Synthesis and biological evaluation of xanthone derivatives as anti-cancer agents targeting topoisomerase II and DNA. Med Chem Res. 2022;31:720\u201334.","journal-title":"Med Chem Res"},{"key":"1446_CR74","doi-asserted-by":"crossref","unstructured":"Sordet O, Solier S. Topoisomerases and Apoptosis. In: Pommier, Y. (eds) DNA Topoisomerases and Cancer. Cancer Drug Discovery and Development. New York, NY: Springer; 2012.","DOI":"10.1007\/978-1-4614-0323-4_19"},{"key":"1446_CR75","first-page":"18","volume":"3","author":"BC Soren","year":"2020","unstructured":"Soren BC, Dasari JB, Ottaviani A, Iacovelli F, Fiorani P. Topoisomerase IB: a relaxing enzyme for stressed DNA. Cancer Drug Resist. 2020;3:18\u201325.","journal-title":"Cancer Drug Resist"},{"key":"1446_CR76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000012076","volume":"58","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology. 2000;58:31\u20137.","journal-title":"Oncology"},{"key":"1446_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1006168","volume":"13","author":"M Toots","year":"2017","unstructured":"Toots M, Ustav JM, M\u00e4nnik A, Mumm K, T\u00e4mm K, Tamm T, et al. Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay. PLoS Pathog. 2017;13:1\u201327.","journal-title":"PLoS Pathog"},{"key":"1446_CR78","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.bjc.6602076","volume":"91","author":"H Tsuda","year":"2004","unstructured":"Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, et al. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer. 2004;91:1032\u20137.","journal-title":"Br J Cancer"},{"key":"1446_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2016.02.14","volume":"28","author":"N Tsuda","year":"2016","unstructured":"Tsuda N, Watari H, Ushijima K. Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chin J Cancer Res. 2016;28:1\u201313.","journal-title":"Chin J Cancer Res"},{"key":"1446_CR80","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1006\/gyno.1999.5556","volume":"75","author":"N Umesaki","year":"1999","unstructured":"Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, et al. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease. Gynecol Oncol. 1999;75:142\u20134.","journal-title":"Gynecol Oncol"},{"key":"1446_CR81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejmech.2014.05.047","volume":"82","author":"HT Van","year":"2014","unstructured":"Van HT, Woo H, Jeong HM, Khadka DB, Yang SH, Zhao C, et al. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors. Eur J Med Chem. 2014;82:181\u201394.","journal-title":"Eur J Med Chem"},{"key":"1446_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2526296123","volume":"123","author":"A Vats","year":"2026","unstructured":"Vats A, Templeton CW, Laimins L. Differential roles of type I topoisomerases in regulating HPV pathogenesis. Proc Natl Acad Sci U S A. 2026;123:1\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1446_CR83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2013.201","volume":"95","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET. Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline\u2010induced cardiotoxicity. Clin Pharmacol Ther. 2014;95:45\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"1446_CR84","first-page":"1","volume":"14","author":"J Venkatas","year":"2020","unstructured":"Venkatas J, Singh M. Cervical cancer: a meta-analysis, therapy and future of nanomedicine. Ecancermedicalscience. 2020;14:1\u201317.","journal-title":"Ecancermedicalscience"},{"key":"1446_CR85","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/1097-0142(20011101)92:9<2327::AID-CNCR1579>3.0.CO;2-6","volume":"92","author":"CF Verschraegen","year":"2001","unstructured":"Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka\u2010Bevers D, Kudelka AP, Hu W, et al. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001;92:2327\u201333.","journal-title":"Cancer"},{"key":"1446_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0149872","volume":"11","author":"P Vici","year":"2016","unstructured":"Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, et al. DNA damage and repair biomarkers in cervical cancer patients treated with neoadjuvant chemotherapy: an exploratory analysis. PLoS One. 2016;11:1\u201311.","journal-title":"PLoS One"},{"key":"1446_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:1\u201344.","journal-title":"J Hematol Oncol"},{"key":"1446_CR88","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.biopha.2016.10.057","volume":"84","author":"L Wasim","year":"2016","unstructured":"Wasim L, Chopra M. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. Biomed Pharmacother. 2016;84:1393\u2013405.","journal-title":"Biomed Pharmacother"},{"key":"1446_CR89","first-page":"1","volume":"31","author":"Y Watanabe","year":"2011","unstructured":"Watanabe Y, Hoshiai H, Nakanishi T, Kawamura N, Tanaka N, Isaka K, et al. Evaluation of oral etoposide in combination with cisplatin for patients with recurrent cervical cancer: long-term follow-up results of a Japanese multicenter study. Anticancer Res. 2011;31:1\u20135.","journal-title":"Anticancer Res"},{"key":"1446_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph16101456","volume":"16","author":"PA Yakkala","year":"2023","unstructured":"Yakkala PA, Penumallu NR, Shafi S, Kamal A. Prospects of topoisomerase inhibitors as promising anti-cancer agents. Pharmaceuticals. 2023;16:1\u201324.","journal-title":"Pharmaceuticals"},{"key":"1446_CR91","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2011.06.011","volume":"123","author":"X Ying","year":"2011","unstructured":"Ying X, Li-Zhi L, Li-Ping C, Min Z, Ji-Hong L. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2011;123:99\u2013104.","journal-title":"Gynecol Oncol"},{"key":"1446_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-020-00800-2","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, et al. TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genomics. 2020;13:1\u201317.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"1446_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-023-04778-0","volume":"21","author":"C Yu","year":"2023","unstructured":"Yu C, Huang F, Wang K, Liu M, Chow WA, Ling X, et al. Single protein encapsulated SN38 for tumor-targeting treatment. J Transl Med. 2023;21(1):1\u201316.","journal-title":"J Transl Med"},{"key":"1446_CR94","first-page":"2955","volume":"19","author":"L Yuniarti","year":"2018","unstructured":"Yuniarti L, Mustofa M, Aryandono T, Haryana SM. Synergistic action of 1,2-epoxy-3 (3- (3,4-dimethoxyphenyl)- 4H-1-benzopiyran-4-on) propane with doxorubicin and cisplatin through increasing of p53, TIMP-3, and microRNA-34a in cervical cancer cell line (HeLa). Asian Pac J Cancer Prev. 2018;19:2955\u201362.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1446_CR95","first-page":"713","volume":"18","author":"YC Zeng","year":"2013","unstructured":"Zeng YC, Yu L, Xiao YP, Xin Y, Wang NQ, Zhang XY, et al. Radiation enhancing effects with the combination of sanazole and irinotecan in hypoxic HeLa human cervical cancer cell line. J BUON. 2013;18:713\u20136.","journal-title":"J BUON"},{"key":"1446_CR96","doi-asserted-by":"publisher","first-page":"720","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","volume":"32","author":"S Zhang","year":"2020","unstructured":"Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2020;32:720\u20138.","journal-title":"Chin J Cancer Res"},{"key":"1446_CR97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cbi.2018.05.011","volume":"290","author":"XL Zhao","year":"2018","unstructured":"Zhao XL, Yu CZ. Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: involvement of AMPK\/Sirt3\/HIF-1 pathway. Chem Biol Interact. 2018;290:57\u201363.","journal-title":"Chem Biol Interact"},{"key":"1446_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2022.105747","volume":"122","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Bai YP, Zhang M, Gao JM, Yang CJ, Zhang ZJ, et al. Design and synthesis of Aza-boeravinone derivatives as potential novel topoisomerase I inhibitors. Bioorg Chem. 2022;122:1\u201312.","journal-title":"Bioorg Chem"},{"issue":"1","key":"1446_CR99","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ygyno.2013.04.009","volume":"130","author":"I Zighelboim","year":"2013","unstructured":"Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130(1):64\u20138.","journal-title":"Gynecol Oncol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01446-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:21:31Z","timestamp":1781637691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01446-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01446-z","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}